VADDI KRISHNA (President, CEO) purchased 7.8% of their position (10K shares) of PRELUDE THERAPEUTICS INC on the open market
Open‑market purchase worth $12.0K — a moderate purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 1/2/2025ACC: 0001562180-25-000008
DirectorOfficer· President, CEO
Since Sep 2020
+10K
Net shares
Net buyer
$12.0K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
10K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+10K
Price / share
$1.20
Trade value
$12K
% of position
7.8%
12/30/2024
127.55K→137.55K
Total
Net shares
+10K
Net value
$12K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 12/30/2024 | P · Purchase | +10K | $1.20 | $12K | 7.8% | 127.55K | 137.55K |
| Total | +10K | $12K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)4
Common Stock
DirectShares owned1.17M
Common Stock
IndirectShares owned423.67K
Common Stock
IndirectShares owned551.78K
Common Stock
IndirectShares owned551.77K
Total
1.17M direct·1.53M indirect2.69M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 1.17M | Direct |
| Common Stock | 423.67K | Indirect |
| Common Stock | 551.78K | Indirect |
| Common Stock | 551.77K | Indirect |
| Total | 2.69M | 1.17M direct·1.53M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported